APSR2026-1000

Yes
Late-Breaking
Submitted
Oral Presentation
AO15-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1243744-46903-APSR2026-1000 AO15-004_439990.pptx
Format: PPTX Only
 
Format: PDF Only
02. Cell and Molecular Biology
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jinglan Huang * Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, College of Basic Medicine, Chongqing Medical University Department of Immunology Chongqing China
Luyao Wang - Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, College of Basic Medicine, Chongqing Medical University Department of Immunology Chongqing China
Ying Xu - Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, College of Basic Medicine, Chongqing Medical University Department of Immunology Chongqing China
Sirong He - Chongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, College of Basic Medicine, Chongqing Medical University Department of Immunology Chongqing China
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Jinglan
Huang
huangjinglan22@foxmail.com
+8615178813186
Under 30
China
Original Research
Development of an Inhalable CD16-CD163 Bispecific Antibody for Local Pulmonary Immunomodulation
Maximum 25 words
Abstract Content
肺泡巨噬细胞 (AM) M1/M2 极化失衡是慢性阻塞性肺疾病 (COPD) 和哮喘中组织损伤的主要驱动因素。现有疗法缺乏亚型特异性,无法覆盖异质性肺泡巨噬细胞。我们设计了一种靶向 M​​1 型和 M2 型肺泡巨噬细胞的 CD16-CD163 双特异性抗体 (bsAb),用于局部肺部免疫调节。
以贝伐珠单抗为骨架,通过引入KiH突变、CrossMab技术(CH1-CL交叉)、链间二硫键以及Fc LALA突变来构建双特异性抗体,从而消除抗体依赖性细胞毒性作用(ADCC)。该抗体在Expi293F细胞中表达,并经蛋白A和SEC-HPLC纯化。采用ELISA和流式细胞术评估其靶点结合情况。鼻内给药后,评估其在肺部的定位和滞留情况。
生物信息学筛选鉴定出CD16(M1特异性)和CD163(M2特异性)。分子对接结果显示,KiH/CrossMab的ΔG值比DVD-Ig低约29.2 kcal/mol,表明其结合能力更强。通过SEC-HPLC分析,该双特异性抗体(bsAb)的单体纯度为99.2%,浓度为1.87 mg/mL。ELISA结果显示,bsAb与CD16的结合亲和力(EC50为0.22 μM)高于CD16 mAb(1.18 μM),与CD163的结合亲和力相当(0.20 μM vs 0.18 μM)。流式细胞术结果显示,bsAb与47.8±3.1%的混合型M1/M2巨噬细胞(AM)结合,显著高于CD16 mAb(33.6±1.2%)或CD163 mAb(26.3±0.8%)。鼻内给药实现了 96.78% 的肺部靶向率,并持续滞留长达 120 小时。细胞成像显示,bsAb 在物理上连接了 M1 型和 M2 型 AM,形成了类似免疫突触的接触。
CD16-CD163双特异性抗体具有结构稳定性高、双靶点亲和力强、能广泛覆盖异质性肺泡巨噬细胞以及鼻内给药后肺部滞留性好等优点,有望成为治疗慢性阻塞性肺疾病和哮喘的精准治疗候选药物。
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Alveolar macrophages, Bispecific antibody,Airway remodeling
maximum 3 keywords and no abbreviations, separated by commas
The authors have no conflicts of interest to disclose.
87